Skip to main content
. 2024 May 16;13(10):e7243. doi: 10.1002/cam4.7243

TABLE 2.

Summary of base‐case analyses.

Base‐case Chemotherapy Toripalimab Incremental
Total costs ($) 161,632 361,813 200,181
PFS‐costs of medication 612 175,401 174,789
Costs of drug management 9363 17,649 8286
Costs of disease management 36,873 72,933 36,060
Costs of progressed disease 83,407 63,231 −20,176
Costs of adverse events 21,356 23,974 2618
Costs of terminal care 10,020 8625 −1395
Total QALYs 1.685 4.390 2.705
PFS‐QALYs 0.506 1.063 0.557
PD‐QALYs 1.179 3.327 2.148

Abbreviations: PD, progressive disease; PFS, progression‐free survival; QALY, quality‐adjusted life year.